Clinical trials: Venous Thromboembolic Event
Pulmonary Embolism
Cook IVC Filter Study
This prospective, multicenter, double-arm clinical study further evaluated the safety and effectiveness of Cook's commercially available inferior vena cava (IVC) filters (specifically, the Günther Tulip® Vena Cava Filter and Cook…
- Trial name
- CIVC (NCT02046096)
- Testing
- Günther Tulip® Vena Cava Filter, Cook Celect® Vena Cava Filters
- Where
- 28 sites in United States, Australia and 1 more
- Volunteers
- 473 people
- Sponsor
- Cook Research Incorporated
Venous Thromboembolism, Pulmonary Embolism
Exclusion of Venous Thrombo-Embolism With a New Clinical Decision Support
The goal of this non interventional study is to demonstrate the diagnostic performances on fresh plasmas in comparison with the performances on frozen plasmas in any patients with VTE suspicion, whatever the pre-test probability.
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- EXTEND (NCT06480994)
- Testing
- Routine Assays on fresh plasma, New Clinical Decision Support on fresh plasma, New Clinical Decision Support on frozen plasma
- Where
- 4 sites in France
- Volunteers
- 1,836 people
- Sponsor
- Diagnostica Stago R&D
Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy
Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for…
- Trial name
- XALIA LEA (NCT02210819)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Recommended VTE pharmacological treatments according to international guidelines
- Where
- 21 sites in Algeria, Egypt and 19 more
- Volunteers
- 1,987 people
- Sponsor
- Bayer
Prophylaxis, Thromboembolism, Venous, Total Knee Replacement
Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)
The primary objective of this study is to evaluate the safety of Xarelto in the prophylaxis of VTE in Indian patients undergoing elective TKR/THR
- Conditions
- Prophylaxis, Thromboembolism, Venous, Total Knee Replacement, Total Hip Replacement
- Trial name
- XYRIS (NCT01523418)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Sponsor
- Bayer
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Cancer
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.
- Trial name
- NCT00942968
- Testing
- dalteparin
- Where
- 42 sites in United States, Austria and 3 more
- Volunteers
- 338 people
- Sponsor
- Pfizer
Symptomatic Venous Thromboembolism (VTE)
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA).
- Trial name
- ROXI-ASPEN (NCT07213778)
- Testing
- REGN7508, Acetylsalicylic Acid (ASA)
- Where
- 51 sites in United States, Greece and 3 more
- Volunteers
- 2,000 people
- Sponsor
- Regeneron Pharmaceuticals
Deep Vein Thrombosis, Pulmonary Embolism
A Performance Evaluation of the LumiraDx Point Of Care D-dimer Assay
In patients with symptoms of Venous Thromboembolism (VTE) (mainly deep vein thrombosis (DVT) or pulmonary embolism (PE)), the study will evaluate the agreement between the D-Dimer measurements from the LumiraDx POC D-Dimer assay…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- EMBOL1 (NCT04737954)
- Testing
- Venepuncture, Fingerstick
- Where
- 13 sites in Germany, United Kingdom
- Volunteers
- 679 people
- Sponsor
- LumiraDx UK Limited
Venous Thromboembolism
Treatment Patterns Among Patients With Venous Thromboembolism in the United States
The purpose of this study is to assess outpatient treatment patterns following hospitalization for venous thromboembolism (VTE). VTE is a condition that occurs when blood clot forms in the vein.
- Trial name
- NCT05795062
- Testing
- apixaban, warfarin
- Where
- United States
- Volunteers
- 13,945 people
- Sponsor
- Pfizer
Venous Thromboembolism
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
- Trial name
- NCT03214172
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Bayer
Pulmonary Embolism, Venous Thromboembolism
Study of IVC Filter Retrieval With the Günther Tulip Vena Cava Filter
The purpose of this study is to test the hypothesis that the Günther Tulip Vena Cava Filter can be removed after a period of implantation, when implanted in patients for the prevention of pulmonary thromboembolism.
- Trial name
- NCT00196118
- Testing
- Günther Tulip Vena Cava Filter
- Where
- 17 sites in United States
- Volunteers
- 800 people
- Sponsor
- Cook Group Incorporated
Pulmonary Embolism
Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China
EINSTEIN PE study demonstrated that rivaroxaban is at least as effective as the current standard therapy with 51% relative risk reduction of major bleeding (1.1% vs.
- Trial name
- XAPEC (NCT03410706)
- Testing
- Rivaroxaban(Xarelto, BAY 59-7939)
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Bayer
Venous Thromboembolism
Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer
The study purpose is to document the prescription and the use of Low Molecular Weight Heparin in usual medical practice in patients with cancer and established Venous Thromboembolism.
- Trial name
- NCT01803022
- Where
- France
- Volunteers
- 419 people
- Sponsor
- LEO Pharma
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)
This is a local, prospective, multicenter, non-interventional, observational study. Primary objective is to describe how in "real life" thromboprophylaxis is carried out after the discharge from a hospital in the patients who…
- Trial name
- SOPRANO (NCT01444586)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Russia
- Volunteers
- 2,293 people
- Sponsor
- Bayer
Thromboembolism
A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients
This study is designed to provide efficacy and safety data for certoparin in the prophylaxis of venous thromboembolism in immobilized, acutely ill medical patients.
- Trial name
- NCT00451412
- Testing
- Certoparin, Unfractionated Heparin
- Where
- Germany
- Volunteers
- 3,254 people
- Sponsor
- Novartis
Venous Thromboembolism
Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities
The study objective is to evaluate the efficacy and safety of oral YM150 for prevention of venous thromboembolism in subjects undergoing hip fracture surgery or surgery in the lower extremities.
- Trial name
- NCT00937911
- Testing
- YM150
- Where
- 8 sites in Japan
- Volunteers
- 101 people
- Sponsor
- Astellas Pharma Inc
Thromboembolism
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin.
- Trial name
- NCT05643885
- Where
- United States
- Volunteers
- 7,304 people
- Sponsor
- Pfizer
Thromboembolism
Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
The purpose of this study is to find the best possible (optimal) dose (effect versus adverse events) of YM150 to prevent the risk of blood clot formation after scheduled hip replacement surgery.
- Trial name
- NCT00353678
- Testing
- YM150
- Where
- 79 sites in Austria, Bosnia and Herzegovina and 15 more
- Volunteers
- 1,141 people
- Sponsor
- Astellas Pharma Inc
Deep Vein Thrombosis, Coronary Artery Bypass Surgery
A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis
This trial is a prospective, single-center Phase II randomized study to demonstrate the superior efficacy of Fondaparinux Sodium subcutaneous injections in patients undergoing CABG surgery (isolated and redo isolated) versus…
- Conditions
- Deep Vein Thrombosis, Coronary Artery Bypass Surgery, Venous Thromboembolism
- Trial name
- NCT00789399
- Testing
- Fondaparinux
- Volunteers
- 78 people
- Sponsor
- Prairie Education and Research Cooperative
Venous Thromboembolism
Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (deep vein thrombosis) or PE (pulmonary embolism) who completed 6 or 12…
- Trial name
- NCT00439725
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 322 sites in United States, Australia and 31 more
- Volunteers
- 1,197 people
- Sponsor
- Bayer